AGOMAB IS LEVERAGING NEW SCIENTIFIC INSIGHTS AND ESTABLISHED DRUG DEVELOPMENT EXPERTISE TO DEVELOP POTENTIAL DISEASE-MODIFYING THERAPIES ADDRESSING WELL-VALIDATED TARGETS AND HIGH UNMET NEED
Agomab is advancing a focused pipeline of organ-restricted investigational therapies designed to modulate pathways in fibro-inflammatory diseases with significant unmet medical need, while maintaining a discovery engine for future pipeline expansion.
Discovery / preclinical pipeline
We are also building a robust discovery pipeline including several early-stage programs. This discovery engine is intended to support continued pipeline growth over time, including the potential to expand into additional fibrotic and fibro-inflammatory indications.
Ontunisertib and AGMB-447 are investigational drugs and are not approved by any regulatory authority; their safety and efficacy have not been established.
“We are focused on advancing our pipeline of proprietary product candidates in fibro-inflammatory diseases with the goal of bringing truly disease-modifying treatments to patients in need.”
Philippe Wiesel, Chief Medical Officer
